5,6-dichloro-3,4-dihydronaphthalen-1(2H)-one | 57915-84-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5,6-dichloro-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 5,6-dichloro-1,2,3,4-tetrahydro-1-naphthalenone；1-Oxo-5,6-dichlortetralin；5,6-dichloro-3,4-dihydro-2H-naphthalen-1-one
• CAS: 57915-84-1
• 化学式: C₁₀H₈Cl₂O
• 分子量: 215.079
• InChiKey: IDQUARMTXIETQJ-UHFFFAOYSA-N

物化性质

• 沸点：
  355.5±42.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,6-dichloro-3,4-dihydronaphthalen-1(2H)-one 在 溴 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 49.67h， 生成 9,10-dichloro-5,6-dihydro-4aH-naphtho[1,2-e][1,3,4]thiadiazin-3-amine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION
  [FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE

  摘要：

  公开号：

  WO2012006068A3
• 作为产物：
  描述：

  2,3-二氯苯甲醛 在 platinum on activated charcoal 盐酸 、 PPA 、 氢气 、 phosphorus pentoxide 、 sodium amide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 5,6-dichloro-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  Synthesis and β-adrenergic properties of tetrahydronaphthalene analogs of dichloroisoproterenol

  摘要：

  The tetrahydronaphthalene analogs 4 and 5 of DCI (3b) and of its N-unsubstituted derivative (3a) were synthesized and tested for their beta-adrenergic properties by means of both binding tests and functional tests. Compounds 4 and 5 proved to possess a good affinity for beta-adrenergic receptors accompanied by an appreciable beta-blocking activity, thus indicating that the formal insertion of a beta-blocking drug such as DCI into a tetrahydronaphthalene structure is able to provide compounds which still possess a beta-blocking activity.

  DOI：

  10.1016/0223-5234(93)90034-c

文献信息

• Aminoalkyl dihydronaphthalenes
  申请人：Abbott Laboratories

  公开号：US04473586A1

  公开（公告）日：1984-09-25

  Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.10 are independently selected from hydrogen, hydroxy, methoxy, loweralkyl of 1 to 4 carbon atoms, or halo, or R.sub.9 and R.sub.10 can be taken together to form a methylenedioxy or ethylenedioxy bridge; or 1,4-benzodioxan of the formula ##STR5## wherein q is 1, 2 or 3, and R.sub.11 is hydrogen, methoxy, or halo; or R.sub.3 and R.sub.4 can be taken together to form a piperazino, piperidino or morpholino moiety; and the pharmaceutically acceptable salts thereof. Also disclosed are novel intermediates useful in the preparation of these compounds.

  本公开涉及由下式表示的1-氨基烷基-3,4-二氢萘烯衍生物，其中n为1或2；R、R.sub.1和R.sub.2分别选自氢、羟基、1至3个碳原子的低烷氧基、1至3个碳原子的低烯氧基、硫甲基、卤素，或下式中的其中一种：其中R.sub.5和R.sub.6分别选自氢、1至4个碳原子的低酰基或下式的磺酰基：其中R.sub.7为1至4个碳原子的低烷基；或R和R.sub.1，或R.sub.1和R.sub.2可结合形成亚甲二氧桥或乙烯二氧桥；但R、R.sub.1或R.sub.2中至少有一个必须为氢以外的其他基团；R.sub.3和R.sub.4分别选自氢、1至4个碳原子的低烷基、1至4个碳原子的卤素取代的低烷基、下式的芳基烷基：其中m为0、1或2，p为0或1，R.sub.8为氢或1至4个碳原子的低烷基，R.sub.9和R.sub.10分别选自氢、羟基、甲氧基、1至4个碳原子的低烷基或卤素，或R.sub.9和R.sub.10可结合形成亚甲二氧桥或乙烯二氧桥；或下式的1,4-苯二氧杂环己烷：其中q为1、2或3，R.sub.11为氢、甲氧基或卤素；或R.sub.3和R.sub.4可结合形成哌嗪基、哌啶基或吗啉基；以及其药用盐。还公开了用于制备这些化合物的新型中间体。
• Compounds for the Inhibition of Cellular Proliferation
  申请人：Chorev Michael

  公开号：US20130178505A1

  公开（公告）日：2013-07-11

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

  提供了抑制翻译的组合物和方法。本文披露的化合物可用于治疗以下疾病：（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染，（4）与病毒感染有关的疾病，以及（5）非增殖性代谢性疾病，如II型糖尿病，其中抑制翻译起始有益。本文还提供了用于治疗上述疾病的方法和试剂盒。
• Compounds for the inhibition of cellular proliferation
  申请人：Chorev Michael

  公开号：US08969573B2

  公开（公告）日：2015-03-03

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

  提供了用于抑制翻译的组合物和方法。本文披露的化合物可用于治疗(1)细胞增殖性疾病、(2)非增殖性退行性疾病、(3)病毒感染、(4)与病毒感染相关的疾病以及/或(5)抑制翻译起始对非增殖性代谢性疾病的治疗有益。本文还提供了用于治疗上述疾病的组合物、方法和试剂盒。
• Synthesis of Rigidified eIF4E/eIF4G Inhibitor-1 (4EGI-1) Mimetic and Their in Vitro Characterization as Inhibitors of Protein–Protein Interaction
  作者：Poornachandran Mahalingam、Khuloud Takrouri、Ting Chen、Rupam Sahoo、Evangelos Papadopoulos、Limo Chen、Gerhard Wagner、Bertal H. Aktas、Jose A. Halperin、Michael Chorev

  DOI：10.1021/jm401733v

  日期：2014.6.26

  The 4EGI-1 is the prototypic inhibitor of eIF4E/eIF4G interaction, a potent inhibitor of translation initiation in vitro and in vivo and an efficacious anticancer agent in animal models of human cancers. We report on the design, synthesis, and in vitro characterization of a series of rigidified mimetic of this prototypic inhibitor in which the phenyl in the 2-(4-(3,4-dichlorophenyl)thiazol-2-yl) moiety was bridged into a tricyclic system. The bridge consisted one of the following: ethylene, methylene oxide, methylenesulfide, methylenesulfoxide, and methylenesulfone. Numerous analogues in this series were found to be markedly more potent than the parent prototypic inhibitor in the inhibition of eIF4E/eIF4G interaction, thus preventing the eIF4F complex formation, a rate limiting step in the translation initiation cascade in eukaryotes, and in inhibition of human cancer cell proliferation.
• 4H-Thieno[3,2-c]chromene based inhibitors of Notum Pectinacetylesterase
  作者：Qiang Han、Praveen K. Pabba、Joseph Barbosa、Ross Mabon、Jason P. Healy、Michael W. Gardyan、Kristen M. Terranova、Robert Brommage、Andrea Y. Thompson、James M. Schmidt、Alan G.E. Wilson、Xiaolian Xu、James E. Tarver、Kenneth G. Carson

  DOI：10.1016/j.bmcl.2016.01.038

  日期：2016.2

  A group of small molecule thienochromenes inhibitors of Notum Pectinacetylesterase are described. We developed SAR on three series based on carbon, oxygen and sulfur replacement of the 5-position. In each series, highly potent Notum Pectinacetylesterase inhibitors were identified. (C) 2016 Elsevier Ltd. All rights reserved.